Gsa Capital Partners LLP Biomarin Pharmaceutical Inc Transaction History

Gsa Capital Partners LLP

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	BUY	$83.81 - $99.0 $589,603 - $696,465	7,035 New	7,035 $614,000
Q3 2023 Nov 15, 2023	SELL	$85.07 - $94.48 $54,274 - $60,278	-638 Reduced 9.1%	6,373 $563,000
Q2 2023 Aug 14, 2023	BUY	$86.68 - $100.3 $379,311 - $438,912	4,376 Added 166.07%	7,011 $607,000
Q1 2023 May 12, 2023	SELL	$87.74 - $117.27 $167,407 - $223,751	-1,908 Reduced 42.0%	2,635 $256,000
Q4 2022 Feb 13, 2023	BUY	$80.93 - $108.63 $367,664 - $493,506	4,543 New	4,543 $470,000
Q2 2022 Aug 09, 2022	SELL	$71.48 - $86.85 $168,120 - $204,271	-2,352 Reduced 10.79%	19,438 $1.61 Million
Q1 2022 May 11, 2022	BUY	$74.28 - $92.69 $1.62 Million - $2.02 Million	21,790 New	21,790 $1.68 Million
Q4 2021 Feb 14, 2022	SELL	$71.72 - $91.47 $773,141 - $986,046	-10,780 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$74.77 - $85.47 $618,347 - $706,836	8,270 Added 329.48%	10,780 $833,000
Q2 2021 Aug 05, 2021	BUY	$75.51 - $84.79 $189,530 - $212,822	2,510 New	2,510 $209,000
Q4 2018 Feb 12, 2019	SELL	$80.14 - $106.07 $183,360 - $242,688	-2,288 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$93.92 - $105.72 $90,351 - $101,702	-962 Reduced 29.6%	2,288 $222,000
Q2 2018 Aug 09, 2018	SELL	$76.01 - $99.03 $37,320 - $48,623	-491 Reduced 13.12%	3,250 $306,000
Q1 2018 May 11, 2018	BUY	$77.67 - $92.63 $290,563 - $346,528	3,741 New	3,741 $303,000

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.